The productivity of our internal discovery capability has enabled us to generate a pipeline of both topical and systemic boron-based compounds. We have discovered six product candidates currently in development. Our lead product candidates include three topically administered dermatologic compounds—tavaborole (formerly AN2690), an antifungal for the treatment of onychomycosis, and AN2728 and AN2898, topical anti-inflammatories for the treatment of psoriasis and atopic dermatitis. In addition, we are developing AN2718 as a second topical antifungal product candidate for the treatment of onychomycosis and skin fungal infections. We have also discovered two compounds that are in development with our partners: GSK2251052, or GSK '052 (formerly referred to as AN3365), a systemic antibiotic for the treatment of infections caused by Gram- negative bacteria, is being developed by GlaxoSmithKline, and AN8194 an animal health product candidate is being developed by Eli Lilly and Company. We have entered into and are seeking partnerships to expand the therapeutic application and commercial value of our boron chemistry platform.